Simply Wall St.
Assessing Stryker (SYK) Valuation After Recent Share Performance And Cash Flow Expectations
➖
AI Sentiment
Neutral
5/10
- Home
- SYK
as of 02-13-2026 3:46pm EST
$365.67
$0.18
-0.05%
Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, extremities, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and orthopedic robotics. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Roughly one-fourth of Stryker's total revenue currently comes from outside the United States.
| Founded: | 1941 | Country: | United States |
| Employees: | N/A | City: | PORTAGE |
| Market Cap: | 141.2B | IPO Year: | N/A |
| Target Price: | $433.91 | AVG Volume (30 days): | 2.2M |
| Analyst Decision: | Buy | Number of Analysts: | 11 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 8.40 | EPS Growth: | 8.25 |
| 52 Week Low/High: | $329.16 - $404.87 | Next Earning Date: | 01-29-2026 |
| Revenue: | $25,116,000,000 | Revenue Growth: | 11.16% |
| Revenue Growth (this year): | 9.82% | Revenue Growth (next year): | 8.42% |
| P/E Ratio: | 43.58 | Index: | |
| Free Cash Flow: | 4.3B | FCF Growth: | +22.83% |
AI-Powered SYK Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 4 days ago
AI Recommendation
hold
Model Accuracy: 69.43%
69.43%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Stryker Corporation (SYK)
STRYKER RONDA E
Sell
Director
SYK Feb 5, 2026
Avg Cost/Share
$364.30
Shares
250,000
Total Value
$90,988,528.01
Owned After
2,207,331
STRYKER RONDA E
Sell
Director
SYK Feb 4, 2026
Avg Cost/Share
$363.57
Shares
250,000
Total Value
$90,730,740.56
Owned After
2,207,331
Pierce James Andrew
Sell
Group President
SYK Feb 2, 2026
Avg Cost/Share
$368.87
Shares
475
Total Value
$175,214.68
Owned After
70,563
SEC Form 4
Wells Preston Wendell
Sell
VP, Chief Financial Officer
SYK Nov 20, 2025
Avg Cost/Share
$365.88
Shares
165
Total Value
$60,370.20
Owned After
6,694
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| STRYKER RONDA E | SYK | Director | Feb 5, 2026 | Sell | $364.30 | 250,000 | $90,988,528.01 | 2,207,331 | |
| STRYKER RONDA E | SYK | Director | Feb 4, 2026 | Sell | $363.57 | 250,000 | $90,730,740.56 | 2,207,331 | |
| Pierce James Andrew | SYK | Group President | Feb 2, 2026 | Sell | $368.87 | 475 | $175,214.68 | 70,563 | |
| Wells Preston Wendell | SYK | VP, Chief Financial Officer | Nov 20, 2025 | Sell | $365.88 | 165 | $60,370.20 | 6,694 |
Latest Stryker Corporation News
SYK Breaking Stock News: Dive into SYK Ticker-Specific Updates for Smart Investing
Zacks
Stryker Launches T2 Alpha Humerus Nailing System for Fracture Care
📈
AI Sentiment
Highly Positive
8/10
PR Newswire
Stryker launches T2 Alpha Humerus Nailing System, supporting surgical workflow and care for complex fractures
📈
AI Sentiment
Highly Positive
9/10
Compare SYK vs Leading Stocks
See how SYK stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "SYK Stryker Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.